Oncotarget

Clinical Research Papers:

Oncogenes and tumor suppressor genes in squamous cell carcinoma of the tongue in young patients

Andreas Knopf _, Justine Lempart, Murat Bas, Julia Slotta-Huspenina, Naglaa Mansour and Marie Kristin Fritsche

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:3443-3451. https://doi.org/10.18632/oncotarget.2850

Metrics: PDF 2813 views  |   HTML 3240 views  |   ?  


Abstract

Andreas Knopf1, Justine Lempart1, Murat Bas1, Julia Slotta-Huspenina2, Naglaa Mansour1, Marie Kristin Fritsche1

1Technische Universität München, Hals-Nasen-Ohrenklinik und Poliklinik, 81675 München, Germany

2Technische Universität München, Institut für Allgemeine Pathologie und Pathologische Anatomie, 81675 München, Germany

Correspondence to:

Andreas Knopf, e-mail: [email protected]

Keywords: Tongue, oncogenes, tumour suppressor genes, oral cancer, young patients

Received: October 23, 2014     Accepted: December 03, 2014     Published: January 30, 2015

ABSTRACT

Objectives: The occurrence of squamous cell carcinoma of the tongue (SCCT) of young patients increased. There are still controversies about patient prognosis. The underlying molecular mechanisms remain unclear.

Methods: 276 patients (66 ≤45, 210 >45 years) with SCCT were included. Clinical parameters and survival data were assessed. Oncogenes and tumor suppressors were analyzed via immunohistochemistry (p53, CXCR4, p16, EGFR) and qPCR (CDK4, CDKN2A, TP53, MDM2, AKT1, PIK3CA, NRAS, HRAS, KRAS, HGF, MET, EGF, ATM, BRCA1, E2F1, FHIT, RUNX3, STK11, BCL2, CTNNB1).

Results: The median overall survival was 142 (≤45 years) and 34 months (>45 years) (p < 0.0001; HR [95%CI]: 0.37 [0.30–0.58]). Disease specific survival in patients ≤45 years was with 181 months significantly higher than in patients >45 years (p < 0.0001; HR [95%CI]: 0.33 [0.26–0.57]). Immunhistochemistry visualized a comparable expression of analyzed proteins. QPCR demonstrated in patients ≤45 years a higher expression of genes that are associated with carcinogenesis (CTNNB1, STK11, CDKN2A, HGF, MET) as well as tumor suppressors that constitute an enhanced radio-sensitivity (ATM, BRCA1E2F1, FHIT).

Conclusion: Derogation of the WNT-CTNNB1-STK11 and CDKN2A-HGF-MET pathway can constitute the carcinogenesis, while the higher expression of radio-sensitizers ATM, BRCA1E2F1 and FHIT can explain the better OS/DSS in young patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2850